CD8A and hepatocellular carcinoma: This is supported by our findings which showed that icaritin increased the frequency of tumor-infiltrating and splenic IFN-γ-producing CD8+ T cells in vivo, thereby indicating that the anti-tumor activity of icaritin is effected by immunomodulation in mice with HCC.